Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company focused on allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has announced inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4) following the hiring of two new employees on August 29, 2025. The company has granted these new hires non-qualified stock options to purchase a total of 84,000 shares of its common stock at an exercise price of $0.72 per share, reflecting the closing price reported by Nasdaq on that date.

The vesting schedule for the stock options is structured to incentivize continued employment. Specifically, one-fourth of the shares will vest on the one-year anniversary of each employee's start date, with the remaining three-fourths vesting in thirty-six substantially equal monthly installments. This ensures that the options will be fully vested by the fourth anniversary of the start date, provided the employees maintain their employment with Adicet.

These inducement grants were made under Adicet's 2022 Inducement Plan, which was established by the board of directors and amended early in 2023. The compensation committee, comprised entirely of independent directors, authorized these awards as a key incentive for the new employees joining the company.

Adicet Bio, Inc. continues to develop its innovative pipeline of “off-the-shelf” gamma delta T cells, which are engineered with chimeric antigen receptors to provide more effective treatment options for patients facing cancer and autoimmune disorders. For further details, visit Adicet’s official website at www.adicetbio.com.

For media inquiries, Anne Bowdidge and Penelope Belnap can be contacted through the provided emails.

Adicet Bio, Inc. (Nasdaq: ACET) has recently made headlines with its inducement grants, conforming to Nasdaq Listing Rule 5635(c)(4). This regulatory compliance signifies the company's commitment to enhancing its workforce through strategic hiring and retention incentives. On August 29, 2025, Adicet granted non-qualified stock options for 84,000 shares at an exercise price of $0.72, directly linking compensation to stock performance, an effective tool for aligning employee interests with shareholder value.

The vesting schedule, where one-fourth of the options will vest after one year and the remainder in equal monthly installments over three years, reflects a long-term investment in talent while also ensuring that new hires are motivated to contribute to the company's ongoing success. This structure supports employee retention and fosters a culture of commitment—essential for a clinical-stage biotechnology firm in the crucial stages of developing gamma delta T cell therapies.

From a market perspective, these inducement grants may signal to investors that Adicet is focused on attracting and retaining skilled personnel crucial for advancing its promising pipeline. In a sector where innovation drives success, the ability to compensate talents adequately is pivotal. With their focus on “off-the-shelf” gamma delta T cells for autoimmune diseases and cancer, successful talent acquisition will enhance their capacity to navigate clinical trials and regulatory hurdles effectively.

Investors should consider the implications of these grants on Adicet’s operational momentum and subsequent potential for growth. While the current stock price of $0.72 reflects the market's sentiment, the successful integration of new employees and advancements in clinical development could provide upward momentum in the share price. Therefore, assessing Adicet as a potential investment may be prudent, particularly as the company makes strides in its therapeutic endeavors.